Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Mundipharma Research GmbH & Co. KG
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 5 ans
A randomized, double-blind, parallel-group, multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of >= 20 mg/day and <= 50 mg/day as oxycodone / naloxone prolonged release compared to subjects taking oxycodone prolonged release tablets alone
The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of const...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 5 ans
A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate non-inferiority in pain and locomotor function and improvement in symptoms of constipation in subjects with moderate to severe pain due to osteoarthritis (OA) of the knee and/or hip taking oxycodone equivalent of 20 - 80 mg/day as oxycodone/naloxone prolonged release (OXN PR) compared to subjects taking oxycodone prolonged release tablets (OxyPR) alone
• To demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function as assessed by the Western Ontario and McM...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 5 ans
An exploratory, randomised, active-controlled, double-blind, double-dummy, parallel group pilot study to determine the ability of oxycodone/naloxone prolonged release tablets (OXN) to reduce the number of subjects developing symptoms of opioid induced constipation compared to morphine prolonged release tablets (MOR PR) in opioid naïve, non-constipated subjects with non malignant pain that require opioid treatment
To demonstrate that in a group of opioid naïve non-constipated subjects with non malignant pain treatment with OXN tablets leads to a higher responder rate compared to MOR PR. A responder is defined ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Mundipharma Research GmbH & Co. KG
MAJ Il y a 5 ans
A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60 - 80 mg/day as oxycodone / naloxone prolonged release (OXN) compared to subjects taking oxycodone prolonged release tablets alone
The primary objective of this study is to demonstrate that subjects with moderate to severe non malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of const...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2